Therapy for Staphylococcus aureus bacteremia: evidence from recent trials and prospects for future research

Organised by the ISAC Working Group on Staphylococcus aureus

In this webinar, organised by the ISAC Working Group on Staphylococcus aureus, experts will review current practices and ongoing controversies in the management of S. aureus bacteremia — a common, high-impact infection with a persistent mortality rate of 15-30% even when treated according to guidelines.

The speakers are leading investigators in cutting‑edge clinical trials designed to define optimal antimicrobial therapy for this condition. They will present findings from these and other key studies, highlight areas where evidence is evolving, and discuss the critical unanswered questions that continue to shape clinical decision-making. The session will also explore future directions and innovative approaches needed to address remaining gaps in the field.

Programme 

1. Dalbavancin for the treatment of S. aureus bacteremia: implications of the DOTS Trial
   Prof. Thomas Holland (Duke University, USA)

2. Early oral switch in S. aureus bloodstream infection
   Prof. Achim Kaasch (Otto von Guericke University Magdeburg, Germany)

3. The SNAP trial: antibiotics for methicillin-susceptible and penicillin-susceptible S. aureus
   Prof. Steven Tong (Peter Doherty Institute for Infection and Immunity, Australia)

Moderators
Prof. Margreet Vos (Chair of ISAC Working Group on S. aureus) and Dr Michael David (Secretary of ISAC Working Group on S. aureus)

**Certificates of attendance will be available

--------------------------------------------------------